Kornimate/medical-research-clean huggingface dataset:
effect of oral propranolol on mrna expresssion in symptomatic cavernous malformation

Conditions: Cerebral Cavernous Malformations

Summary: this is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of the investigators, and who meet all of the inclusion and exclusion criteria. patients will be randomized into two groups: a treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg er capsule per day) for 7- to 10-days prior to surgery plus their usual medications, and a control group of 10 (n=10) patients will receive only their routine medications. currently, the only active treatment alternative for symptomatic cerebral cavernous malformations is surgery. a control group is required to allow for a semi-quantitative comparison with mrna and mirna levels in the treatment group.

this is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of the investigators, and who meet all of the inclusion and exclusion criteria. patients will be randomized into two groups: a treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg er capsule per day) for 7- to 10-days prior to surgery plus their usual medications, and a control group of 10 (n=10) patients will receive only their routine medications. currently, the only active treatment alternative for symptomatic cerebral cavernous malformations is surgery. a control group is required to allow for a semi-quantitative comparison with mrna and mirna levels in the treatment group.

Eligibility criteria:
inclusion criteria: 1. subject is at least 18-years of age. 2. clinical and imaging diagnosis of a symptomatic isolated cavernous malformation or familial cavernous malformation 3. mri imaging grade type i or type ii (see table 1) 4. patient is considered a candidate for surgical resection of their cavernous malformation 5. written and informed consent obtained prior to the study enrollment. 6. negative pregnancy test at time of enrollment for women of child-bearing potential. 7. heart rate greater than 50 beats per minute 8. systolic blood pressure \> 90 mmhg exclusion criteria: 1. subject is less than 18-years of age. 2. history of allergy to propranolol or other beta blockers. 3. patient is already taking another beta blocker for cardiac indications. 4. history of asthma presently requiring any active treatment (oral medications or inhalers). 5. history of cardiac dysfunction (as defined by the new york heart association functional classification grade ii, iii or iv). 6. heart rate \< 50 beats per minute 7. systolic blood pressure \< 90 mmhg 8. history of diabetes and currently on any anti-hyperglycemic medication. 9. pregnant and lactating women.
sodium hyaluronate and wavefront aberrations in dry eyes

Conditions: Dry Eye

Summary: eyes with abnormal tear film function have been found to show larger optical aberrations than normal eyes which may be attributed to the unstable and irregular tear film, uneven ocular surface, and increased scatter due to the exposure of the rough surface of corneal epithelium after tear break-up. these hypotheses have been supported by the findings that instillation of artificial tears (sodium hyaluronate preparation) in dry eye patients reduces both corneal and ocular aberrations, improving the optical quality of the retinal image. however, the previous studies only evaluated the short-term effects of a single administration of an artificial tear but did not determine the duration of action or inflection point at which the ocular aberrations increase back to baseline. also, there has clearly been no such clinical trial that has been a well randomized controlled study to date. this report is the first randomized controlled trial that investigated the long-term effects of a single dose of sodium hyaluronate-based artificial tears on wavefront aberrations in patients with dry eye.

parameters used to determine treatment outcomes included ocular aberrations and severity of dry eye symptoms.

Eligibility criteria:
inclusion criteria: 1. male or female patients aged 18 years or over. 2. documented history of bilateral dry eye for at least 3 months. 3. schirmer's i test (without anesthesia) less than 10 mm wetting/5 minutes for each eye. 4. tear film break-up time (tbut) less than 10 seconds for each eye. 5. good compliance with the study regimen and availability for the duration of the entire study period. exclusion criteria: 1. pregnant or lactating women. 2. contact lens wear. 3. non-mydriatic pupil size less than 5.0 mm. 4. other ocular surface pathologies or coexisting ocular diseases. 5. ocular surgery or trauma within the past 4 months. 6. use of concomitant eye drops or eye ointments within the past 2 weeks. 7. abnormality of the nasolacrimal drainage apparatus. 8. permanent or temporary occlusion of lacrimal puncta in any eye. 9. known hypersensitivity to hyaluronic acid or any component used in the study. 10. taking the following systemic medications within the previous 2 months: tricyclic antidepressive agents, anti-histaminic agents, phenothiazines, cholinergic agents, antimuscarinic agents, nsaids, beta-blockers, immunomodulators, anti-acneic agents, diuretics, corticosteroids and tetracyclines. 11. very severe dry eye causing inaccurate aberrometry measurements.

Keywords: dry eye ocular aberration
fasted exercise and ldl-c

Conditions: Cardiovascular Diseases

Summary: cardiovascular disease (cvd) is the leading cause of death in the uk and worldwide with low density lipoprotein cholesterol (ldl-c) being one of the most important modifiable risk factors. physical activity is inexpensive and research shows that it consistently improves high density lipoprotein and triglyceride concentrations. however, fails to improve ldl-c concentrations. preliminary research suggests fasted exercise could potentially improve ldl-c concentrations. the majority of research in these areas have also mostly been done in males with the results generalised to females. as it is known that lipid metabolism and cvd risk is different between sexes it is possible that the response to fasted exercise may also be different between sexes. this aim of this study is to assess the effect of physical activity performed before or after a meal on plasma ldl-c concentrations in men and women and explore sex differences. the study will also assess the effect of fasted exercise on other cvd risk factors.


Eligibility criteria:
inclusion criteria: * age 18-65 years * body mass index 20-40kg/m2 * physically inactive (exercise for less than 150 minutes per week) exclusion criteria: * weight instability (\>5kg change in body mass over last 6 months) * diagnosis of diabetes or cvd * pregnant or lactating * any medical condition or medication that could introduce bias into the study (eg. lipid disorders, lipid or glucose metabolism altering medications eg statins)
brain metabolism in polycystic ovary syndrome

Conditions: Insulin Resistance

Summary: the purpose of this study is to investigate whether higher insulin resistance in young women with polycystic ovary syndrome (pcos) is associated with reduced cerebral metabolic rate of glucose (cmrglu). brain volumes using magnetic resonance imaging (mri) and quantitative cerebral glucose uptake using dynamic positron emission tomography (pet) were obtained.

mri and fdg pet scan for each participant were obtained within an average time frame of 3 weeks. isulin resistance were assessed with the updated homeostasis model assessment (homa2-ir).

Eligibility criteria:
inclusion criteria: * diagnosis of pcos * age ≤ 35 y * bmi ≤ 35 exclusion criteria: * taking medications for diabetes or insulin-sensitizing drugs * drug addictions * psychiatric illness * smoking * overt evidence of heart, liver or renal disease

Keywords: insulin resistance brain metabolism pet mri
assessing the effectiveness of concurrent peer review for patients with cardiovascular disease and diabetes

Conditions: Cardiovascular Diseases

Summary: we will assess the impact of concurrent peer review vists on blood pressure, cholesterol and diabetes control. concurrent peer review (cpr) visits refer to special offic visits by patients to a clinician (physician, nurse practitioner, or physician assistant) other than than their primary care provider that are specifically designed to improve care for diabetes and cardiovascular disease.

this project aims to reduce racial and ethnic disparities in health care by improving cardiovascular and diabetes management among poor and minority patients. we propose to implement and evaluate an innovative, but practical intervention: cpr visits. cpr visits are designed to minimize competing demands for clinicians and reduce clinical inertia by focusing clinician and patient attention on optimizing cardiovascular and/or diabetes management and disease control and through use of clinician prompts and decision support at the point of care. following training of clinician staff, cpr visits will be implemented within two sites of a single community health center (westside health services, inc). patients will be randomly assigned one cpr visit with a clinician other than their primary care clinician or to usual care. the primary study outcome will include control of hypertension, diabetes, and lipids. secondary outcomes will include process measures for cardiovascular and diabetes care. both personnel and data collection infrastructure will build on the existing health disparities collaborative at westside. a research team from the university of rochester will assist in the implementation of study design. this team will lead both the quantitative and qualitative evaluation of the project including outcome and process measures. project findings offer promise for improving care to underserved populations through dissemination and implementation of a feasible strategy among practices caring for the underserved. findings will be disseminated nationally in conjunction with the robert wood johnson foundation, the national association of community health centers, and the national health disparities collaborative and through publication in the peer reviewed literature and presentation at national conferences.

Eligibility criteria:
inclusion criteria: * active patient at westside health services. * currently enrolled in the health disparities collaborative at whs. * at least one visit to primary care provider in past year. * any of the following documented during the preceding three months: * bp not at goal e,g. (bp 140/80 or greater unless has dm, cad or cri then bp greater than 130/80), ldl-c not at goal (level dependent on absolute atp iii cvd risk) or glycated hemoglogin 7 percent or higher exclusion criteria: * less than 18 years of age

Keywords: cardiovascular disease diabetes quality improvement peer review
vitamin d3 supplementation in dialysis patients

Conditions: End-Stage Renal Disease

Summary: vitamin d deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide. this study will evaluate the effect of 26 weeks of vitamin d3 supplementation in patients with end stage renal disease.


Eligibility criteria:
inclusion criteria: * hemodialysis or peritoneal dialysis \> 3 months exclusion criteria: * hypercalceamia * cancer * inability to give informed consent

Keywords: hemodialysis peritoneal dialysis vitamin d deficiency blood pressure arterial stiffness heart function renin-angiotensin system calcium fgf-23 brain natriuretic peptide
use of copeptin in diabetes insipidus

Conditions: Diabetes Insipidus; Primary Polydipsia

Summary: prospective evaluation of the novel biomarker copeptin in the differential diagnosis of diabetes insipidus against the standard diagnostic test methods.

purpose of this study is to compare the overall diagnostic accuracy of the three following diagnostic test procedures in diabetes insipidus (central, nephrogenic) and primary polydipsia: a) classical water deprivation test alone, b) classical water deprivation test plus plasma copeptin cut-off levels, c) hypertonic saline infusion test plus plasma copeptin measurement. the investigators hypothesize that firstly b) and c) is better as a). secondly the investigators hypothesize that c) is non-inferior to b).

Eligibility criteria:
inclusion criteria: * polyuria or/and polydipsia or/and therapy with synthetic adenovirus proteinase (avp) derivate * urine osmolality \<800mosm/kgh20 exclusion criteria: * polyuria due to diabetes mellitus * hypokalemia * hyperkalemia (\>5mmol/l) * hypercalcemia * kidney disease (min.: glomerular filtration rate (gfr) 60ml/min/1.73m2) * pregnancy * hyponatremia \>135mmol/l * hypernatremia \>145mmol/l * hypo- or hypervolemia * uncorrected adrenal or thyroidal deficiency * cardia failure * epilepsia * uncontrolled hypertension

Keywords: copeptin differential diagnosis of polyuria polydipsia syndrome diabetes insipidus compulsive water drinking water deprivation test diabetes insipidus (central and nephrogenic)
frequency of selected single nucleotide polymorphisms in huntington disease gene expansion carriers

Conditions: Huntington Disease

Summary: for participation in this epidemiological study, a single-day visit at the study site is required. participants will be recruited from huntington disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. at the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (snps) on the wild-type huntington (wthtt) and mutant huntington (mhtt) alleles.


Eligibility criteria:
inclusion criteria: * have signed the informed consent form (icf) * aged 25 to 60 years, inclusive, at the time of signing the icf * confirmation of huntington disease (hd) gene expansion mutation carrier status * confirmation of total functional capacity (tfc) ≥9 and total motor score (tms) \>6 within 12 months prior to signing the icf * ability to tolerate blood draws exclusion criteria: * none
effects of whole body vibration on autonomic function in healthy young and elderly

Conditions: Healthy; Aging

Summary: aging causes anatomical and physiological changes in the cardiovascular system and autonomic function with decline in its maximum function. this study aimed to evaluate the acute effects of whole body vibration on cardiovascular system, autonomic function and heart variability in healthy young and elderly. the investigators' hypothesis is that whole body vibration has different effects in young and elderly.


Eligibility criteria:
inclusion criteria: * elderly individuals aged between 60 and 80 years * young individuals aged between 18 and 30 years * able to walk without assistance * good understanding to perform the proposed procedures * sedentary or low active exclusion criteria: * body mass index (bmi) \> 35kg/m2 * systolic blood pressure \> 140 mmhg or diastolic blood pressure \> 90 mmhg (at rest) * difficulty adapting to the whole body vibration * smoking * neuromuscular or degenerative disorders * neurological diseases * cardiopulmonary comorbidities * cardiac arrhythmias * osteoarticular disorders * use of hormone replacement therapy * use medications or supplements known to affect cardiovascular parameters * labyrinthitis
long-term follow-up study of patients who received pb127 ultrasound imaging agent

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to collect longer term follow-up information concerning health and survival on selected patients who received pb127 for injectable suspension in the pivotal trial (127-014).


Eligibility criteria:
inclusion criteria: patients enrolled in protocol 127-014 who 1. were enrolled in stratum 1 2. did not undergo angiography during study evaluation 3. did not have a clinical oucome during the initial 6 month follow-up period as described in protocol 127-014.

Keywords: ultrasound perfusion spect coronary artery disease chest pain low probability angiography clinical outcomes
ivl vs elca for stent underexpantsion (ivl-elca dragon)

Conditions: Coronary Artery Calcification; Intravascular Lithotripsy; Excimer Laser-coronary Atherectomy; Stent Restenosis; Stent Occlusion

Summary: the ivl- elca dragon registry is a multicenter study that enrolled consecutive patients with stent underexpansion treated with ivl ora elca in high-volume pci centers. the primary efficacy endpoint was device success (technical success with a final stent expansion ≥ 80%). thirty days device-oriented composite endpoint (doce: cardiac death, target lesion revascularization, or target vessel myocardial infarction) was the secondary endpoint.


Eligibility criteria:
stent underexpansion as stent expansion of \<80% assessed with intravascular imaging (minimum in-stent lumen area divided by average reference lumen area x100%).
environmental health effects on your physiology

Conditions: Obesity

Summary: this study evaluates the associations between exposure to air pollutants, green space, and the gut microbiome and metabolome.

a rapidly evolving field of study suggests a link between the gut microbiome and fecal metabolome with obesity. recent studies show that environmental exposures, such as ambient air pollution (aap) exposure can affect gut bacteria and modify risk for obesity. additionally, proximity to green space has been shown to reduce exposure to air pollutants and increase gut microbial diversity. the investigator's preliminary work has shown that near-roadway air pollution exposure was positively correlated with gut microbial taxa that have been linked with obesity. these findings suggest that air pollution exposure may increase susceptibility to obesity through alterations in the composition and function of the gut microbiome. despite this, no studies have systematically examined the impact of air pollutants and green space on the gut microbiome and metabolome among adolescents. the overall goal of this research is to determine whether exposure to air pollutants and/or green space affect the gut microbiome and metabolome in young adults residing in denver, colorado. this study will examine residential-based estimates of air pollution exposure and green space and also perform detailed gut microbial and metabolite profiling in 100 adolescent and young adults.

Eligibility criteria:
inclusion criteria: * the participant population includes young adults (18-25 years of age) who live in denver, colorado. exclusion criteria: * exclusion criteria include physical, mental, or cognitive disability that prevents participation * current incarceration * antibiotic usage in the previous month * pregnant or nursing * non-english speaking * any medical conditions known to affect body composition, insulin secretion, or the gut microbiota (i.e., type 1 or 2 diabetes, intestinal bowel disease, crohn's disease, kidney disease, heart disease, autoimmune disease).
comparison of 4 tactical tourniquets used in war medicine

Conditions: Hemorrhage

Summary: bleeding remains the leading cause of death in combat, and the literature suggests that tourniquetable hemorrhage is the second leading cause of preventable death, behind non- tourniquetable hemorrhage. currently, most western armed forces recommend the use of the tactical tourniquet in combat for the management of tourniquetable hemorrhage. the softt® tourniquet (tactical medical solutions, anderson) is the tactical tourniquet currently in use by the french armed forces. as the contract will soon come to an end, the question of its renewal arises. the purpose of this study is to compare 4 commercially available tactical tourniquets in healthy volunteers. the hypothesis of the research is that one of the 4 tourniquets compared is faster to set up than the others.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * student of the military health school of lyon bron (ecoles militaires de santé de lyon bron; emslb); * periodic medical examination up to date with the mention "fitness for duty"; * holder of the "combat rescue level 1" training. exclusion criteria: * vascular pathology; * current progressive pathology of any kind; * history of thrombo-embolic disease; * presence of cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking \> 1 cigarette/day, bmi \> 25); * iliofemoral and axillary vascular abnormalities detected by systematic doppler ultrasound; * presence of symptoms suggestive of covid-19; * positive covid-19 antigen test; * in contact with a person diagnosed positive for covid-19 within 15 days prior to inclusion; * pregnant or breastfeeding woman.

Keywords: tactical tourniquet
study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of akb-9778 ophthalmic solution

Conditions: Ocular Hypertension; Primary Open Angle Glaucoma

Summary: the purpose of this phase 1b study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of akb-9778 ophthalmic solution (eye drops) administered for 7 days in adults. the study is a double-masked, multiple- ascending dose trial and will enroll four cohorts of up to 12 subjects. dose cohorts will receive increasing doses of akb-9778 ophthalmic solution or vehicle-matched placebo daily for 7 days. cohort 5 will enroll subjects with open angle glaucoma or ocular hypertension who will continue current prostaglandin therapy during the study. cohort 5 subjects will receive the maximum tolerated dose from the previous cohorts.


Eligibility criteria:
key inclusion criteria: * aged \> 18 years to 70 years inclusive in cohort 1; aged ≥ 45 to 70 years inclusive in cohorts 2-4, aged 18 to 80 years inclusive in cohort 5. * for subjects in cohort 1, iop between 12 and 23 mm hg (inclusive). for subjects in cohorts 2-4, iop between 16 and 23mm hg (inclusive). for subjects in cohort 5, iop between 17 and 27 mm hg (inclusive). * central corneal thickness of 480 to 600 μm, inclusive * for subjects in cohort 5, diagnosis of oag or oht * for subjects in cohort 5, currently receiving prostaglandin therapy for iop lowering key exclusion criteria: * diagnosis of any form of glaucoma in cohorts 1-4 * clinically significant eye trauma within 6 months of screening * any intraocular ophthalmic procedure within 6 months of screening * any ocular inflammation within 90 days of screening or a history of recurrent uveitis in either eye * subjects with any known chronic ocular disease (other than incipient cataract or refractive error) * any condition preventing valid applanation tonometry measurement, e.g., clinically significant corneal disease, refractive surgery * visual acuity (va) worse than 20/30 in either eye, for cohort 5 va worse than 20/100 in either eye